195156-77-5|Valomaciclovir stearate|(R)-4-((L-valyl)oxy)-2-((2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl)butyl stearate|-范德生物科技公司

Valomaciclovir stearate

NMR下载 COA and HPLC MSDS下载
names：
(R)-4-((L-valyl)oxy)-2-((2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl)butyl stearate
CAS号：
195156-77-5
MDL Number：
MF(分子式)： C33H58N6O5 MW(分子量)： 618.864
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	(R)-4-((L-valyl)oxy)-2-((2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl)butyl stearate
英文别名	Valomaciclovir stearate; A-174606.0; ABT-606; EPB-348; MIV-606; RP-606; A174606.0; ABT606; EPB348; MIV606; RP606.
CAS号	195156-77-5
Inchi	InChI=1S/C33H58N6O5/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-27(40)44-23-26(20-21-43-32(42)28(34)25(2)3)22-39-24-36-29-30(39)37-33(35)38-31(29)41/h24-26,28H,4-23,34H2,1-3H3,(H3,35,37,38,41)/t26-,28+/m1/s1
InchiKey	ACBSZTQIFTYFGH-IAPPQJPRSA-N
分子式 Formula	C33H58N6O5
分子量 Molecular Weight	618.864
溶解度Solubility
性状	White to off-white solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Valomaciclovir stearate(CAS:195156-77-5 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Valomaciclovir stearate (A-174606.0; ABT-606; EPB-348; MIV-606; RP-606) is a DNA polymerase inhibitor potentially for treatment of acute herpes zoster and EB virus infection. Valomaciclovir stearate is an orally available, small molecule drug with broad-spectrum antiviral activity against a variety of important herpesviruses, including Epstein-Barr virus, or EBV (the first virus to be directly associated with human cancer), varicella zoster virus, or herpes zoster (cause of shingles), and herpes simplex virus 1 and 2.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]De SK, Hart JC, Breuer J. Herpes simplex virus and varicella zoster virus: recent advances in therapy. Curr Opin Infect Dis. 2015 Dec;28(6):589-95. doi: 10.1097/QCO.000000000000021[1]Review. PubMed PMID: 26524331.

[2]Andrei G, Snoeck R. Advances in the treatment of varicella-zoster virus infections. Adv Pharmacol. 2013;67:107-68. doi: 10.1016/B978-0-12-405880-4.00004-4. Review. PubMed PMID: 23886000.

[3] Tyring SK, Plunkett S, Scribner AR, Broker RE, Herrod JN, Handke LT, Wise JM, Martin PA; Valomaciclovir Zoster Study Group. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial. J Med Virol. 2012 Aug;84(8):1224-32. doi: 10.1002/jmv.23329. PubMed PMID: 22711350.

[4] Price NB, Prichard MN. Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol. 2011 Dec;1(6):548-54. doi: 10.1016/j.coviro.2011.10.015. Review. PubMed PMID: 22162744; PubMed Central PMCID: PMC3230035.

[5] Andrei G, Snoeck R. Emerging drugs for varicella-zoster virus infections. Expert Opin Emerg Drugs. 2011 Sep;16(3):507-35. doi: 10.1517/14728214.2011.591786. Epub 2011 Jun 24. Review. PubMed PMID: 21699441.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开